中经记者 晏国文 卢志坤 北京报道 | 单位: 万元 | 截至 | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 截至2024 截至2024 | 2024年 | 程至2024年12 | 廠 | 195 | 是否 | 開后付 | 年12月31 | 12月31 | 適開金 | 年12月31 | 里程碑事项 | 客户 | 付歐期限 | 付歇节点 | 月31日累计确 | | 9 | 日实际付 | $ | 增期 | 散金额 | 日应收账 | 日已十 | 题 | 认令题 | 散进度 | 款余额 | 提的坏 | | | | | | 账准备 | 根据益方生物与贝达 | 贝福替尼非小编 | | | | | | | | | | | | | | | 药业签订的《合作协 | 贝福替尼非小 | 履肺癌二线治疗 | 议》的定,则福替尼 | 细胞肺癌二线 议》的定，贝福替尼 适应症于2023年5 治疗适应症上 - 疗毒服装上 或应该 ...

东风已来，在政策支持与市场需求的共同推动下，深市一批医药生物企业正乘"数"而行、提"智"增效。 积极推进数智化转型 医药行业是关系国计民生的重要产业，是培育发展战略性新兴产业的重点领域，也是我国国民经济的重 要组成部分。 近日，工业和信息化部、商务部、国家卫生健康委等七部门联合印发《医药工业数智化转型实施方案 （2025—2030年）》，释放出"推动新一代信息技术与医药产业链深度融合"的积极信号。 2024年，多个"十四五"规划类文件出台，《深化医药卫生体制改革2024年重点工作任务》等一系列重大 的产业支持政策相继发布，首次将创新药列为新兴产业关键环节和新质生产力重要组成部分，持续鼓励 医药行业向高质量、创新驱动方向转型，聚焦医药、医疗、医保协同发展和治理，三医联动协同发展促 进行业的规范化与高效化。 人工智能等前沿技术加持，医药生物产业迎来哪些变化呢？ 创新成果驱动业绩增长 原创性技术产品和颠覆性研发成果持续涌现，深市医药企业实现了持续的业绩增长。 贝达药业是一家以自主知识产权创新药物研究与开发为核心，集研发、生产、市场营销于一体的国家级 高新技术企业。公司深耕肿瘤创新药二十多年，构建了覆盖表皮生长因子受 ...

Core Viewpoint - Beida Pharmaceutical reported a revenue growth of 17.74% year-on-year to 2.892 billion yuan in 2024, with a net profit of 403 million yuan, marking a 15.67% increase, and a significant turnaround in profitability with a 55.92% rise in non-net profit [1][2] Financial Performance - The company achieved a revenue of 2.892 billion yuan in 2024, approaching the 3 billion yuan mark, with a net profit of 403 million yuan [1] - The non-net profit reached 410 million yuan, indicating a strong recovery from previous years where revenue growth did not translate into profit [1] - Historical revenue figures from 2021 to 2023 were 2.246 billion yuan, 2.377 billion yuan, and 2.456 billion yuan, with net profits fluctuating significantly [1] Product Portfolio - Beida Pharmaceutical currently has five new drugs in the oncology treatment field, including the first-generation EGFR inhibitor, Alectinib (Kaimena®), and the ALK inhibitor, Ensartinib (Beimina®) [1][2] - The company has expanded its product lineup from a single product to five through independent research and strategic partnerships [2] - Alectinib has generated over 1 billion yuan in annual revenue since its inclusion in the national medical insurance directory in 2017 [2] Market Expansion and Pipeline - The company has one innovative drug under review for market approval and over 20 projects in development, indicating potential for future growth [2][6] - The sales forecast for Beimina in 2024 is expected to approach 800 million yuan, while Kaimena's sales are projected to be between 1.2 billion and 1.4 billion yuan [4][5] - Beida's research and development investment has consistently been high, with R&D expenditures from 2020 to 2024 being 742 million yuan, 861 million yuan, 977 million yuan, 1 billion yuan, and 717 million yuan, respectively [7] Leadership and Strategic Moves - The return of Professor Mao Li as the Chief R&D Officer is a significant development for the company, as he previously held key positions within Beida and has extensive experience in the industry [8][9]